semaglutide prices Ozempic And Wegovy Will Be Cut By Up To 50% Next Year Novo Nordisk rolls out $349

BPC-157 is not approved by the FDA for any medical use

Retatrutide is a triple receptor agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide activates only the GLP-1 receptor and tirzepatide activates both GLP-1 and GIP receptors

The finer the graduation marks, the more accurately you can measure

Although the two drugs work through different mechanisms, they complement rather than duplicate each other

16 17 18 Newly emerging indications for GLP-1 medicationsincluding heart disease, metabolic liver disease, peripheral artery disease, Alzheimers/dementia risk, and even alcohol and substance use disorders, as highlighted in a 2025 study in JAMA 19 suggest these drugs may soon play a much broader role in medicine than just treating diabetes or obesity